{"id":"cagrisema","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Gastrointestinal disorders"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By simultaneously activating GLP-1 and glucagon receptors, CagriSema enhances insulin secretion, reduces glucagon secretion when appropriate, slows gastric emptying, and increases energy expenditure. This dual mechanism produces greater metabolic effects than GLP-1 monotherapy alone, resulting in improved blood glucose control and more substantial weight reduction in patients with type 2 diabetes.","oneSentence":"CagriSema is a dual GLP-1/GCG receptor agonist that activates both glucagon-like peptide-1 and glucagon receptors to improve glycemic control and promote weight loss.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:47.132Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Cagrilintide%2Fsemaglutide","title":"Cagrilintide/semaglutide","extract":"Cagrilintide/semaglutide, known as CagriSema, is a combination of cagrilintide, a dual amylin and calcitonin receptor agonist, and semaglutide, a GLP-1 agonist. It has been proposed as a follow-on to Ozempic, Mounjaro, and Wegovy in obesity and Type II diabetes treatment."},"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Obesity or weight management (in development)"}]},"trialDetails":[{"nctId":"NCT06409130","phase":"PHASE2","title":"Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-05-20","conditions":"Alcohol-related Liver Disease","enrollment":270},{"nctId":"NCT05669755","phase":"PHASE3","title":"REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2023-03-01","conditions":"Cardiovascular Disease","enrollment":7101},{"nctId":"NCT06403761","phase":"PHASE1","title":"Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-05-06","conditions":"Diabetes Mellitus, Type 2","enrollment":158},{"nctId":"NCT07357766","phase":"PHASE3","title":"A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight","status":"NOT_YET_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-06-22","conditions":"Overweight, Obesity","enrollment":1400},{"nctId":"NCT07357740","phase":"PHASE2","title":"A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-08-27","conditions":"Diabetes Mellitus, Type 2","enrollment":400},{"nctId":"NCT06388187","phase":"PHASE3","title":"A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2024-06-24","conditions":"Obesity","enrollment":300},{"nctId":"NCT07282613","phase":"PHASE3","title":"A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-08-04","conditions":"Diabetes Mellitus, Type 2","enrollment":80},{"nctId":"NCT06131437","phase":"PHASE3","title":"A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-11-27","conditions":"Obesity","enrollment":809},{"nctId":"NCT05394519","phase":"PHASE3","title":"A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-02-01","conditions":"Overweight, Obesity, Type 2 Diabetes Mellitus","enrollment":1200},{"nctId":"NCT07253285","phase":"PHASE3","title":"A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-01-08","conditions":"Overweight, Obesity","enrollment":460},{"nctId":"NCT06221969","phase":"PHASE3","title":"A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2024-01-16","conditions":"Type 2 Diabetes","enrollment":1000},{"nctId":"NCT05813925","phase":"PHASE3","title":"A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-04-03","conditions":"Obesity or Overweight","enrollment":331},{"nctId":"NCT06065540","phase":"PHASE3","title":"A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-09-27","conditions":"Type 2 Diabetes Mellitus","enrollment":2734},{"nctId":"NCT06780449","phase":"PHASE3","title":"A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-02-10","conditions":"Obesity","enrollment":400},{"nctId":"NCT06323174","phase":"PHASE3","title":"A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-03-19","conditions":"Type 2 Diabetes","enrollment":189},{"nctId":"NCT05996848","phase":"PHASE3","title":"A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-08-15","conditions":"Obesity or Overweight","enrollment":300},{"nctId":"NCT06207877","phase":"PHASE1","title":"A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-02-23","conditions":"Obesity","enrollment":62},{"nctId":"NCT06267092","phase":"PHASE1","title":"A Study of How CagriSema Works on Appetite in People With Excess Body Weight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-02-15","conditions":"Overweight, Obesity","enrollment":164},{"nctId":"NCT06534411","phase":"PHASE3","title":"A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2024-11-05","conditions":"Diabetes Mellitus, Type 2","enrollment":1023},{"nctId":"NCT07011667","phase":"PHASE3","title":"A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-06-03","conditions":"Obesity","enrollment":609},{"nctId":"NCT05567796","phase":"PHASE3","title":"A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2022-11-01","conditions":"Obesity","enrollment":3400},{"nctId":"NCT06797869","phase":"PHASE2","title":"A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-01-29","conditions":"Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy","enrollment":142},{"nctId":"NCT06323161","phase":"PHASE3","title":"A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-03-26","conditions":"Type 2 Diabetes","enrollment":274},{"nctId":"NCT06131372","phase":"PHASE2","title":"A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-04-01","conditions":"Chronic Kidney Disease, Type 2 Diabetes, Obesity","enrollment":626},{"nctId":"NCT07184086","phase":"PHASE1","title":"A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-09-26","conditions":"Obesity","enrollment":80},{"nctId":"NCT06716307","phase":"PHASE1","title":"A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-12-02","conditions":"Obesity","enrollment":18},{"nctId":"NCT07010432","phase":"PHASE1","title":"The Role of the Amylin Analogue Cagrilintide in Bone Metabolism","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-06-12","conditions":"Obesity","enrollment":144},{"nctId":"NCT06289504","phase":"PHASE1","title":"A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-02-27","conditions":"Obesity","enrollment":34}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":33,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CagriSema","genericName":"CagriSema","companyName":"Novo Nordisk A/S","companyId":"novo-nordisk-a-s","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CagriSema is a dual GLP-1/GCG receptor agonist that activates both glucagon-like peptide-1 and glucagon receptors to improve glycemic control and promote weight loss. Used for Type 2 diabetes mellitus, Obesity or weight management (in development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}